Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
Lung Cancer
; 166: 84-93, 2022 04.
Article
in En
| MEDLINE
| ID: mdl-35245844
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumonia
/
Carcinoma, Non-Small-Cell Lung
/
Dermatitis
/
Exanthema
/
Lung Neoplasms
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Lung Cancer
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Country of publication: